XML 12 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEBT - Narrative (Detail) (USD $)
0 Months Ended 6 Months Ended 0 Months Ended 6 Months Ended 0 Months Ended 0 Months Ended
Jun. 30, 2014
Dec. 31, 2013
Jun. 30, 2014
Revolving Credit Facility
Dec. 31, 2013
Revolving Credit Facility
Jun. 21, 2013
Revolving Credit Facility
Jun. 21, 2013
Revolving Credit Facility
Option (ii), (x)
Jun. 21, 2013
Revolving Credit Facility
Option (ii), (z)
Jun. 30, 2014
Revolving Credit Facility
Minimum
Jun. 21, 2013
Revolving Credit Facility
Minimum
Option (i)
Jun. 30, 2014
Revolving Credit Facility
Maximum
Jun. 21, 2013
Revolving Credit Facility
Maximum
Option (i)
Jun. 08, 2011
Revolving Credit Facility
August 2010 Amendment
Jun. 08, 2011
Revolving Credit Facility
June 2011 Amendment
Jun. 08, 2011
Revolving Credit Facility
June 2011 Amendment
Minimum
Jun. 08, 2011
Revolving Credit Facility
June 2011 Amendment
Maximum
May 11, 2012
Revolving Credit Facility
May 2012 Amendment
Maximum
Jun. 21, 2013
Revolving Credit Facility
June 2013 Amendment
Maximum
Jun. 21, 2013
Revolving Credit Facility
June 2013 Amendment
Leverage Ratio after March 31, 2015
Jun. 21, 2013
Revolving Credit Facility
June 2013 Amendment
Maximum Levarage Ratio July 01, 2014 through March 31.2015
Jun. 15, 2011
2016 Convertible Senior Notes
Jun. 30, 2014
2016 Convertible Senior Notes
Dec. 31, 2013
2016 Convertible Senior Notes
Debt Instrument [Line Items]                                            
Senior credit facility, maximum borrowing capacity                           $ 450,000,000 $ 600,000,000              
Reallocated term loan                         150,000,000                  
Additional commitments                         200,000,000                  
Line of credit facility, expiration date                       Aug. 10, 2015 Jun. 08, 2016                  
Leverage ratio                               3.75 4.25 3.75 4.00      
Interest rates available to the Company at its option           0.50% 1.00%   1.00%   1.75%                      
Cash balance threshold above which excess amount is not subject to any restriction of use or investment         40,000,000                                  
Line of credit, commitment fee percentage               0.15%   0.30%                        
Line of credit facility outstanding     421,900,000 186,900,000                                    
Weighted average interest rate on debt     1.70% 2.00%                                    
Available borrowings under senior secured revolving credit facility     178,100,000                                      
Fair value of outstanding borrowings     421,700,000                                   246,000,000  
Principal amount outstanding                                       230,000,000 230,000,000 230,000,000
Interest rate on debt                                       1.625%    
Portion of the debt proceeds that was classified as equity at the time of the offering                                       43,200,000    
Effective interest rate implicit in the liability component                                       5.60%    
Carrying amount of liability 209,096,000 205,182,000 [1]                                     209,100,000 205,200,000
Unamortized discount                                         20,900,000 24,800,000
Common stock based on initial conversion rate ratio (in shares)                                       17.4092    
Principal amount to be considered for conversion purpose                                       1,000    
Initial conversion price, per share                                       $ 57.44    
Maximum selling price of company's common stock                                       150.00%    
Principal amount of notes per average trading price                                       $ 1,000    
Maximum average conversion value of the Notes                                       98.00%    
Earliest conversion date                                       June 15, 2016    
Strike price of the call transaction (in dollars per share)                                       $ 57.44    
Strike price of warrant transactions (in dollars per share)                                       $ 70.05    
[1] See Note 1 of these condensed consolidated financial statements for discussion of the impact of the change in accounting for the medical device excise tax.